Residual renal function in dialysis patients


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Residual renal function (RRF) improves outcome in renal replacement therapy. Factors which unfluence on RRF include dialysis adequacy, control of hydratation, stability of blood pressure and cardiac functions, drug renal complications. Association of new dialysis technologies, with stable RRF and low-protein diet with the addition of ketoanalogues of essential aminoacids are perspective for individual modes of hemodialysis and continuous ambulatory peritoneal dialysis.

Full Text

Restricted Access

About the authors

Alexey Yu. Nikolaev

Russian Medical Academy of Continuous Professional Education

Email: nickolaev.aleksei2011@yandex.ru
Doctor of Medical Sciences, Professor at the Department ofNephrology and Hemodialysis Moscow, Russian Federation

Natalya N. Filatova

Russian Medical Academy of Continuous Professional Education

Email: natalia.n.filatova@gmail.com
PhD in Medical Sciences, Associate Professor at the Department of Nephrology and Hemodialysis Moscow, Russian Federation

References

  1. Янковой А.Г., Ватазин А.В., Смоляков А.А., Мартынюк А.П., Лосев Г.Ю. Современное состояние проблемы нефрэктомии при подготовке больных ХБП к трансплантации почки. Альманах клинической медицины. 2005;8(4):105-112.
  2. Knehtl M., Bevc S., Hojs R., Hlebic G., Ekart R. Bilateral nephrectomy for uncontrolled hypertension in hemodialysis patient: a forgotten option? Nephrol. Ther. 2014;10(7):528-531. doi: 10.1016/j.nephro.2014.07.484.
  3. Shaft T., Jaar B.G., Plantinga L.C., Fink N.E., Sadler J.H., Parekh R.S., Powe N.R., Coresh J. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the choices for healthy outcomes in caring for end-stage renal disease (CHOICE) study. Am. J. Kidney Dis. 2010;56(2):348-358. doi: 10.1053/j.ajkd.2010.03.020.
  4. Obi Y., Streja E., Rhee C.M., Ravel V., Amin A.N., Cupisti A., Chen J., Mathew A.T., Kovesdy C.P., Mehrotra R., Kalantar-Zadeh K. Incremental hemodialysis, residual kidney function, and mortality risk in incident dialysis patients: A cohort study. Am. J. Kidney Dis. 2016;68(2):256-265. doi: 10.1053/j.ajkd.2016.01.008.
  5. Rocco M., Soucie J.M., Pastan S., McClellan W.M. Peritoneal dialysis adequacy and risk of death. Kidney Int. 2000;58(1):446-457. doi: 10.1046/j.1523-1755.2000.00184.x.
  6. Bargman J.M., Thorpe K.E., Churchill D.N.; CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J. Am. Soc. Nephrol. 2001;12(10):2158-2162.
  7. Jansen M.A., HartA.A., Korevaar J.C., DekkerF.W., Boeschoten E.W., Kredi-et R.T. NECOSAD Study Group. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 2002;62(3):1046-53. doi: 10.1054/j.1223-1722.2002.00202.x.
  8. Van der Wal W.M., Noordzij M., Dekker F.W., Boeschoten E.W., Krediet R.T., Korevaar J.C., Geskus R.B. Netherlands Cooperative Study on the Adequacy of Dialysis Study Group (NECOSAD). Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol. Dial. Transplant. 2011;26(9):2978-2983. doi: 10.1093/ndt/gfq856.
  9. Termorshuizen F., Dekker F.W., van Manen J.G., Korevaar J.C., Boeschoten E.W., Krediet R.T. NECOSAD Study Group.Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands cooperative study on the adequacy of dialysis (NECOSAD)-2. J. Am. Soc. Nephrol. 2004;12(4):1041-1070. doi: 10.1097/01.asn.0000117976.29592.93.
  10. Vilar E., Wellsted D., Chandna S.M., Greenwood R.N., Farrington K. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol. Dial. Transplant. 2009;24(8):2502-2510. doi: 10.1093/ndt/gfp071.
  11. Stompor T., Sutowicz W., Anyszek T., Kusnierz B., Fedak D., Naskalski J.W. Dialysis adequacy, residual renal function and serum concentrations of selected low molecular weight proteins in patients undergoing continuous ambulatory peritoneal dialysis. Med. Sci. Monit. 2003;9(11):CR500-4.
  12. Penne E.L., van der Weerd N.C., Grooteman M.P., Mazairac A.H., van den Dorpel M.A., Nube M.J., Bots M.L., Levesque R., ter Wee P.M., Blankestijn P.J. CONTRAST investigators. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2011;6(2):281-289. doi: 10.2212/CJN.04400210.
  13. Wang A.Y., Wang M., Woo J., Lam C.W., Lui S.F., Li P.K., Sanderson J.E. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J. Am. Soc. Nephrol. 2004;15(8):2186-2194. doi: 10.1097/01.ASN.0000135053.98172.D6.
  14. Grooteman M.P, van den Dorpel M.A., Bots M.L., Penne E.L.,van derWeerd N.C., Mazairac A.H., den Hoedt C.H., van der Tweel I., Levesque R., Nube M.J., ter Wee P.M., Blankestijn P.J.; CONTRAST Investigators. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J. Am. Soc. Nephrol. 2012;23(6):1087-1096. doi: 10.1681/ASN.2011121140.
  15. Kalantar-Zadeh K., Ikizler T.A., Block G., Avram M.M., Kopple J.D. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am. J. Kidney Dis. 2003;42(5):864-881. Doi: 10.1016//. aakd.2003.07.016.
  16. McIntyre C.W. Haemodialysis-induced myocardial stunning in chronic kidney disease - a new aspect of cardiovascular disease. Blood Purif. 2010;29(2):105-110. doi: 10.1159/000245634.
  17. Kovesdy C.P Malnutrition in dialysis patients - the need for intervention despite uncertain benefits. Semin. Dial. 2016;29(1):28-34. doi: 10.1111/sdi.12410.
  18. Cтроков А.Г, Гуревич К.Я., Ильин А.П., Денисов А.Ю. Лечение пациентов хронической болезнью почек 5-й стадии методом гемодиализа (гемофильтрации). В книге: Нефрология. Клинические рекомендации. Под ред. E.М. Шилова, А.В. Смирнова, Н.Л. Козловской. М., 2016 С. 633-655.
  19. Locatelli F., Martin-Malo A., Hannedouche T., Loureiro A., Papadimitriou M., Wizemann V., Jacobson S.H., Czekalski S., Ronco C., Vanholder R. Membrane Permeability Outcome (MPO) Study Group. Effect of membrane permeability on survival of hemodialysis patients. J. Am. Soc. Nephrol. 2009;20(3):645-654. doi: 10.1681/ASN.2008060590.
  20. Leven C., Hudier L., Picard S., Longuet H., Lorcy N., Cam G., Boukerroucha Z., Dolley-Hitze T., Le Cacheux P., Halimi J.M., Cornec Le Gall E., Hanrotel-Saliou C., Arreule A., Massad M., Duveau A., Couvrat-Desvergnes G., Renaudineau E. Prospective study of drug-induced interstitial nephritis in eleven French nephrology units. Presse Med. 2014;43(11):e369-376. doi: 10.1016/j.lpm.2014.03.032.
  21. Gooch K., Culleton B.F., Manns B.J., Zhang J., Alfonso H., Tonelli M., Frank C., Klarenbach S., Hemmelgarn B.R. NSAID use and progression of chronic kidney disease. Am. J. Med. 2007;20(3):280.e1-7. Doi: 10.1016/j. amjmed.2006.02.015.
  22. Lopez-Novoa J.M., Quiros Y., Vicente L., Morales A.I., Lopez-Hernandez F.J. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. Doi: 10.1038/ ki.2010.337.doi: 10.1038/ki.2010.337.
  23. Иммуносупрессия при трансплантации солидных органов. Под ред. С.В. Готье. Тверь, 2011. 470 c.
  24. Pallet N., Djamali A., Legendre C. Challenges in diagnosing acute calcineurin-inhibitor induced nephrotoxicity: from toxicogenomics to emerging biomarkers. Pharmacol. Res. 2011;64(1):25-30. doi: 10.1016/j.phrs.2011.03.013.
  25. Agarwal R., Brunelli S.M., Williams K., Mitchell M.D., Feldman H.I., Umscheid C.A. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol. Dial. Transplant. 2009;24(3):856-863. doi: 10.1093/ndt/gfn593.
  26. Rudnick M.R., Goldfarb S., Tumlin J. Contrast-induced nephropathy: is the picture any clearer? Clin. J. Am. Soc. Nephrol. 2008;3(1):261-262. doi: 10.2215/CJN.04951107.
  27. Шутов Е.В. Перитонеальный диализ. М., 2010. 153 с. [Shutov E.V. Peritoneal. Dial. M., 2010. 153р. (In Russ.)].
  28. Palomo-Pinon S., Mora-Villalpando C.J., Del Carmen Prado-Uribe M., Ceballos-Reyes G.M., De Jesus Ventura-Garcia M., Avila-Diaz M., Rodriguez O.O., Paniagua-Sierra J.R. Inflammation and myocardial damage markers influence loss of residual renal function in peritoneal dialysis patients. Arch. Med. Res. 2014;45(6):484-488. doi: 10.1016/S.arcmed.2014.07.003.
  29. Heaf J.G., Wehberg S. Relative survival of peritoneal dialysis and haemodialysis patients: effect of cohort and mode of dialysis initiation. PLoS One. 2014;9(3):e90-119. doi: 10.1371/journal.pone.0090119.
  30. Зубкин М.Л., Червинко В.И., Крюков Е.В., Фролова Н.Ф., Котенко О.Н. Хроническая HCV-инфекция в условиях заместительной почечной терапии. Нефрология и диализ. 2016;18(4):374-386.
  31. Николаев А.Ю., Милованов Ю.С. Лечение почечной недостаточности. Руководство для врачей. 2-е издание. М., 2011. 589 c
  32. McCullough P.A., Sandberg K.R., Yee J., Hudson M.P. Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J. Ren. Angiotens. Aldoster. Syst. 2002;3(3):188-191. doi: 10.3317/jraas.2002.040.
  33. Chary tan D., Kuntz R.E., Mauri L., DeFilippi C. Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am. J. Kidney Dis. 2007;49(3):409-416. doi: 10.1053/j.ajkd.2006.11.042.
  34. Liu J.Y., Birkmeyer N.J., Sanders J.H., Morton J.R., Henriques H.F., Lahey S.J., Dow R.W., Maloney C., DiScipio A.W., Clough R., Leavitt B.J., O’Connor G.T. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England cardiovascular disease study group. Circulation. 2000;102(24):2973-2977. doi: 10.1161/01.cir.102.24.2973.
  35. Бокерия Л.А., РевишвилиА.Ш., Ломидзе Н.Н., Рзаев Ф.Г., Щербинев В.М., Григорьев А.Ю. Застойная сердечная недостаточность: применение медикаментозной терапии, электрокардиостимуляторов или имплантируемых кардиовертеров-дефибрилляторов? Анналы аритмологии. 2006;1:27-33.
  36. Шутов Е.В., Николаев А.Ю., Филатова Н.Н. Кардиоренальный синдром у больных на заместительной почечной терапии. Нефрология и диализ. 2010;20(3):242-274
  37. Hanko J., Romann A., Taylor P., Copland M., Beaulieu M. Optimizing AVF creation prior to dialysis start: the role of predialysis renal replacement therapy choices. Nephrol. Dial. Transplant. 2012;27(11):4205-4510. doi: 10.1093/ndt/gfs378.
  38. KDOQI clinical practice guidelines for vascular access: 2006 update. Am. J. Kidney Dis. 2006;48(Suppl. 1):S176-247. Doi: https://doi.org/10.1053/. ajkd.2006.04.029
  39. Maduell F., Moreso F., Pons M., Ramos R., Mora-Macia J., Carreras J., Soler J., Torres F., Campistol J.M., Martinez-Castelao A.; ESHOL Study Group. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J. Am. Soc. Nephrol. 2013;24(3):487-497. doi: 10.1681/ASN.2012080875.
  40. De Brito-Ashurst I., Varagunam M., Raftery M.J., Yaqoob M.M. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J. Am. Soc. Nephrol. 2009;20(9):2075-2084. doi: 10.1681/ASN.2008111205.
  41. Bellizzi V., Chiodini P., Cupisti A., Viola B.F., Pezzotta M., De Nicola L., Minutolo R., Barsotti G., Piccoli G.B., Di Iorio B. Very low-protein diet plus ketoacids in chronic kidney disease and risk of death during end-stage renal disease: a historical cohort controlled study. Nephrol. Dial. Transplant. 2015;30(1):71-77. doi: 10.1093/ndt/gfu251.
  42. Ермоленко В.М. Диета с ограничением белка: история, лечение пред-диализных больных, влияние на режим заместительной почечной терапии. Нефрология и диализ. 2019;21(3):281-291. doi: 10.28996/2618-9801-2019-3-281-291.
  43. Mathew A., Obi Y., Rhee C.M., Chen J.L., Shah G., Lau W.L., Kovesdy C.P., Mehrotra R., Kalantar-Zadeh K. Treatment frequency and mortality among incident hemodialysis patients in the United States comparing incremental with standard and more frequent dialysis. Kidney Int. 2016;90(5):1071-1079. doi: 10.1016/j.kint.2016.05.028.
  44. Nakao T., Kanazawa Y., Takahashi T. Once-weekly hemodialysis combined with low-protein and low-salt dietary treatment as a favorable therapeutic modality for selected patients with end-stage renal failure: a prospective observational study in Japanese patients. BMC. Nephrol. 2018;19(1):151. doi: 10.1186/s12882-018-0941-2.
  45. Zhang M., Wang M., Li H., Yu P., Yuan L., Hao C., Chen J., Kalantar-Zadeh K. Association of initial twice-weekly hemodialysis treatment with preservation of residual kidney function in ESRD patients. Am. J. Nephrol. 2014;40(2):140-150. doi: 10.1159/000365819.
  46. Cornelis T., Kotanko P., Goffin E., Kooman J.P., van der Sande F.M., Chan C.T. Can intensive hemodialysis prevent loss offunctionality in the elderly ESRD patient? Semin. Dial. 2011;24(6):645-652. Doi: 10.1111/. 1525-139X.2011.00995.x.
  47. Hall Y.N., Larive B., Painter P., Kaysen G.A., Lindsay R.M., Nissenson A.R., Unruh M.L., Rocco M.V., Chertow G.M.; Frequent Hemodialysis Network Trial Group.Effects of six versus three times per week hemodialysis on physical performance, health, andfunctioning: Frequent Hemodialysis Network (FHN) randomized trials. Clin. J. Am. Soc. Nephrol. doi: 10.2215/CJN.10601011.
  48. Тиктинский О.Л., Александров В.П. Мочекаменная болезнь. СПб., 2000. 384 с.
  49. Sarma A.V., Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001. Semi. Urol. Oncol. 2002;20(1):3-9. doi: 10.1053/suro.2002.30390.
  50. Thorpe A., Neal D. Benignprostatic hyperplasia. Lancet. 2003;361(9366):1359- 1367. doi: 10.1016/S0140-6736(03)13073-5.
  51. Шестакова М.В., Дедов И.И. Сахарный диабет и хроническая болезнь почек. М., 2009. 484 c.
  52. Cooper C.J., Murphy T.P., Cutlip D.E., Jamerson K., Henrich W., Reid D.M., Cohen D.J., Matsumoto A.H., Steffes M., Jaff M.R., Prince M.R., Lewis E.F., Tuttle K.R., Shapiro J.I., Rundback J.H., Massaro J.M., DAgostino R.B.Sr, Dworkin L.D. CORAL Investigators.Stenting and medical therapy for atherosclerotic renal-artery stenosis. N. Engl. J. Med. 2014;370(1):13-22. doi: 10.1056/NEJMoa1310753.
  53. White C.J. Optimizing outcomes for renal artery intervention. Circ. Cardiovasc. Interv. 2010;3(2):184-192. Doi: 10.1161/ CIRCINTERVENTIONS.109.910208.
  54. Klahr S., Morrissey J. Obstructive nephropathy and renal fibrosis: The role of bone morphogenic protein-7 and hepatocyte growth factor. Kidney Int. 2003;87(l):S105-112. doi: 10.1046/j.1523-1755.64.s87.16.x.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies